QQ客服 官方微博 反馈留言

	Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?
	Wu, Guangzhen; Wang, Qinglian; Xu, Yingkun; Li, Jianyi; Zhang, Hongge; Qi, Guanghui; Xia, Qinghua
刊名	CELL DEATH & DISEASE
	2019
卷号	10
DOI	10.1038/s41419-019-1654-6
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4540207
专题	山东大学
作者单位	1.Shandong Univ, Shandong Prov Hosp, Dept Urol, Jinan, Shandong, Peoples R China. 2.[Wu, Guangzh
推荐引用方式 GB/T 7714	Wu, Guangzhen,Wang, Qinglian,Xu, Yingkun,et al. Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?[J]. CELL DEATH & DISEASE,2019,10.
APA	Wu, Guangzhen.,Wang, Qinglian.,Xu, Yingkun.,Li, Jianyi.,Zhang, Hongge.,...&Xia, Qinghua.(2019).Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?.CELL DEATH & DISEASE,10.
MLA	Wu, Guangzhen,et al."Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?".CELL DEATH & DISEASE 10(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。